FDA will convene the Pharmacy Compounding Advisory Committee (PCAC) on July 23-24, 2026, to discuss seven peptides for potential inclusion on the 503A bulks list. An additional five peptides will be ...

The US Food and Drug Administration (FDA) has called on its Pharmacy Compounding Advisory Committee to discuss whether a ...

The US Food and Drug Administration (FDA) late Friday issued revised versions of two final guidance documents explaining the use of bulk drug substances in compounding and clarifying that the agency ...

The US Food and Drug Administration will review whether seven currently restricted peptides can be compounded by pharmacies, potentially expanding access to popular wellness treatments. The advisory ...

Walk into almost any wellness clinic or anti-aging practice in the United States and you will find them: vials of compounded ...

The Food and Drug Administration has opened the door to a possible regulatory shift on a group of peptide injections that ...

The FDA’s Pharmacy Compounding Advisory Committee will meet this summer to discuss whether certain peptides from compounding ...

FDA's April 1, 2026, update to its compounding policy page follows more than 18 months of regulatory activity surrounding the compounding of GLP-1 medications ...

Shares of Hims & Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved ...

On Feb. 6, 2026, FDA announced that it would take action to restrict access to GLP-1 ingredients for non-FDA approved compounded drugs. On the same day, the HHS General Counsel announced on social ...